USA flag logo/image

An Official Website of the United States Government

VACCINE POTENTIAL OF TOXOPLASMA GONDII RECOMBINANT P3

Award Information

Agency:
Department of Health and Human Services
Branch:
N/A
Award ID:
16283
Program Year/Program:
1993 / SBIR
Agency Tracking Number:
16283
Solicitation Year:
N/A
Solicitation Topic Code:
N/A
Solicitation Number:
N/A
Small Business Information
Paravax Inc.
2301 Research Blvd Fort Collins, CO 80526
View profile »
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No
 
Phase 2
Fiscal Year: 1993
Title: VACCINE POTENTIAL OF TOXOPLASMA GONDII RECOMBINANT P3
Agency: HHS
Contract: N/A
Award Amount: $500,000.00
 

Abstract:

P30, THE MAJOR SURFACE ANTIGEN OF THE TOXOPLASMA GONDII TACHYZOITE STAGE, HAS BEEN ISOLATED FROM THE PARASITE AND SHOWN TO PROTECT MICE FROM A VIRULENT T. GONDII CHALLENGE. THE CDNA ENCODING P30 HAD BEEN CLONED AND EXPRESSED IN E. COLI, PRODUCING RECOMBINANT PROTEIN THAT WAS POORLY RECOGNIZED BY ANTIBODY TO NATIVE PROTEIN. THE SPECIFIC AIM OF THIS PROJECT IS TO DEMONSTRATE THAT RECOMBINANT P30 CAN BE EXPRESSED MAMMALIAN CELLS IN SINDIS VIRUS-BASED VECTORS, AND THAT THE EXPRESSED PROTEIN RESEMBLES MORE CLOSELY NATIVE PROTEIN ISOLATED FROM PARASITE MATERIAL. THE LONG TERM GOAL IS TO TEST THE IMMUNOGENIC POTENTIAL OF SINDIS-P30 RECOMBINANT PROTEIN, FIRST IN THE MOUSE CHALLENGE MODEL FOLLOWED BY TESTING IN TARGET HOST ANIMAL SPECIES. SUCCESS IN THIS ENDEAVOR WILL ALLOW COMMERCIAL DEVELOPMENT OF VACCINES TO PREVENT TOXOPLASMOSIS IN SHEEP, SWINE, CATTLE, AND PERHAPS CATS. IN ADDITION POSITIVE RESULTS WILL EXTEND THE EXPERIMENTAL AND PRACTICAL UTILITY OF THE RECENTLY DEVELOPED SINDIS VIRUS VECTOR SYSTEMS.

Principal Investigator:

Xiong, Cheng
Principal Investigator
4159617272

Business Contact:

1 r43 ai30834-01
Small Business Information at Submission:

Paravax, Inc.
2301 Research Blvd Ft Collins, CO 80526

EIN/Tax ID:
DUNS: N/A
Number of Employees: N/A
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No